Tamoxifen News and Research

RSS

Tamoxifen is a drug used to treat certain types of breast cancer in women and men. It is also used to prevent breast cancer in women who have had ductal carcinoma in situ (abnormal cells in the ducts of the breast) and in women who are at a high risk of developing breast cancer. Tamoxifen is also being studied in the treatment of other types of cancer. It blocks the effects of the hormone estrogen in the breast. Tamoxifen is a type of antiestrogen. Also called tamoxifen citrate.

Hormonal treatments reduce risk of cancer returning

Women diagnosed with breast cancer who carry a certain genetic mutation can have breast-sparing surgery but should consider hormonal treatments to reduce their risk of cancer returning.

6 Jun 2006

Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients

A protein that activates estrogen receptors in breast cancer may play a role in resistance to therapeutic effects of anti-estrogen tamoxifen treatment, according to a study in the Journal of the National Cancer Institute.

17 May 2006

Osteoporosis drug Raloxifene shown to be as effective as Tamoxifen in preventing invasive breast cancer

Initial results of the Study of Tamoxifen and Raloxifene, or STAR, show that the drug raloxifene, currently used to prevent and treat osteoporosis in postmenopausal women, works as well as tamoxifen in reducing breast cancer risk for postmenopausal women at increased risk of the disease.

18 Apr 2006

Researchers release results of (STAR) breast cancer prevention trial

Below are comments from Len Lichtenfeld, MD, American Cancer Society deputy chief medical officer, in response to the results of the STAR trial.

18 Apr 2006

Evista may be a better option than Tamoxifen for reducing breast cancer risk

According to drug company Lilly it's osteoporosis drug Evista is as effective as Tamoxifen in reducing the risk of breast cancer in high-risk women.

17 Apr 2006

Advances in chemotherapy significantly reduce risk of disease recurrence in breast cancer patients

Recent advances in chemotherapy have significantly reduced the risk of disease recurrence and death in breast cancer patients whose tumors are not hormone sensitive, according to a study by researchers at Dana-Farber Cancer Institute and 10 other institutions.

13 Apr 2006

Environmental scientists identify new culprits in the cancer equation

In the granite-rich region of Western North Carolina, taking a daily shower could pose a risk of developing lung cancer. So could working from home every day. That's because granite emits a carcinogenic gas, radon.

13 Apr 2006

Benefit of chemotherapy in breast cancer depends on estrogen status of tumors

When it comes to chemotherapy treatment for women whose breast cancer has spread to their lymph nodes, the estrogen status of their tumors matters, says a team of researchers in the Journal of the American Medical Association.

11 Apr 2006

HOXB13 and IL17BR genes predict outcome for breast cancer patients

The 2-gene expression profile of HOXB13 and IL17BR in a woman's breast cancer predicts risk of recurrence in node-negative patients treated with tamoxifen.

4 Apr 2006

First solid data on health effects of a low-fat diet

Adopting a low-fat diet in later life and following such a regimen for nearly a decade does not appear to have a significant impact on reducing the overall risk of breast cancer, colorectal cancer or heart disease, according to a Women's Health Initiative study that involved nearly 50,000 postmenopausal women across the United States.

9 Feb 2006

Researchers show how estrogen turns genes on and off during cancer progression

Ohio - A new study suggests that the hormone estrogen works in partnership with other proteins to activate or suppress gene activity in breast cancer cells.

2 Feb 2006

BRCA1 gene inhibits estrogen and progesterone

It's been known that the breast cancer susceptibility gene BRCA1 regulates use of estrogen in breast and other cells, but now researchers at Georgetown University Medical Center have discovered that it also controls activity of a second sex steroid hormone, progesterone.

27 Jan 2006

Breast ducts - A new site for cancer treatment!

Johns Hopkins Kimmel Cancer Center researchers are studying whether delivering chemotherapy drugs directly to breast "plumbing" might make treatment of early breast cancer easier on the patient and at least as good as surgery or radiation.

26 Jan 2006

Warning of risk of from vaginal oestrogen

Breast cancer specialists from one of the UK's leading cancer centres cautioned doctors of the risks in prescribing vaginal oestrogen to breast cancer patients being treated with the new aromatase inhibiting drugs, anastrozole, letrozole and exemestane.

26 Jan 2006

alphaB-crystallin may be a useful molecular marker to identify women with aggressive breast cancer

A groundbreaking study led by Northwestern University researchers has demonstrated that a protein called alphaB-crystallin, which normally protects cells from stress damage, triggers events that may cause breast cancer when overactive.

6 Jan 2006

New breast cancer drug Femara will save lives

Following the results of a worldwide study, U.S. regulators have given approval for the use of the drug Femara for women with early breast cancer directly after they have had surgery.

29 Dec 2005

A good year for breast cancer detection and treatment

It was a good year in women’s health, notably breast cancer treatment and detection. The December issue of Mayo Clinic Women’s HealthSource hails these important advances of 2005.

29 Dec 2005

Common gene variation lessens Tamoxifen’s benefit

Researchers have discovered that one of the most commonly prescribed drugs for breast cancer, tamoxifen, may not be as effective for women who inherit a common genetic variation.

19 Dec 2005

More good news - Femara helps prevent the return of breast cancer

In more good news for women suffering from breast cancer a study by the the Swiss drugmaker Novartis has shown that their drug Femara benefits women with hormone-sensitive early breast cancer.

14 Dec 2005

NHS under pressure to provide new breast cancer drugs

The National Health Service in the UK is being put under considerable pressure by Cancer charities to widen access to a promising new class of breast cancer drug as new evidence suggests the latest treatment is far superior to Tamoxifen, the long established premier drug for women with the early stage of the disease.

12 Dec 2005